(Alliance News) - Mereo BioPharma Group PLC on Friday said it still expects trials of its Setrusumab osteogenesis imperfecta treatment to kick off in the second half of 2020, despite the Covid-19 outbreak.
The company said its Phase 2b ASTEROID study is fully-recruited. Osteogenesis imperfecta is a bone disorder.
Mereo added that Non-Executive Director Michael Wyzga will become the company's interim chief financial officer when Richard Jones departs from the role.
"Jones will remain in his position as CFO with the company for a transitionary period up to five months. As the company continues to expand its investor base in the US following the listing of the company's American depositary shares on Nasdaq in April 2019, Mereo intends to commence a search for a new CFO to be based in the US."
Mereo shares closed 1.8% higher at 19.35 pence each in London on Friday.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.